| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CUE | Common Stock | Options Exercise | $66.1K | +8K | +8.51% | $8.26 | 102K | Nov 15, 2021 | Direct | F1 |
| transaction | CUE | Common Stock | Sale | -$144K | -8K | -7.84% | $18.05 | 94K | Nov 15, 2021 | Direct | F1, F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CUE | Stock Option (right to buy) | Options Exercise | $0 | -8K | -44.44% | $0.00 | 10K | Nov 15, 2021 | Common Stock | 8K | $8.26 | Direct | F1, F3 |
| Id | Content |
|---|---|
| F1 | The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.21, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. |
| F3 | The option vests in eight equal semi-annual installments beginning November 14, 2018. |